• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792

Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- (CAS No. 282525-07-9)

Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- (CAS No. 282525-07-9) is a versatile organic compound that has gained significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, often referred to as Boc-protected cyclohexanepropanoic acid, is characterized by its unique structural features and functional groups, making it a valuable intermediate in the synthesis of various bioactive molecules and pharmaceuticals.

The chemical structure of Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- consists of a cyclohexane ring attached to a propanoic acid moiety, with a Boc (tert-butyloxycarbonyl) protecting group on the amino functionality. The Boc group is widely used in peptide synthesis and organic synthesis to protect the amino group from unwanted reactions during multi-step synthetic processes. This protection strategy allows for the controlled deprotection and subsequent functionalization of the amino group, enabling the synthesis of complex molecules with high purity and yield.

Recent studies have highlighted the importance of Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- in the development of novel therapeutic agents. For instance, a study published in the Journal of Medicinal Chemistry in 2023 demonstrated that this compound can serve as a key intermediate in the synthesis of potent inhibitors of protein-protein interactions (PPIs). PPI inhibitors are a promising class of drugs that target specific protein interactions involved in various diseases, including cancer and neurodegenerative disorders.

In another notable application, researchers at the University of California, San Francisco (UCSF) utilized Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- to synthesize a series of small molecules with selective activity against specific kinases. Kinases are enzymes that play crucial roles in cellular signaling pathways and are often dysregulated in diseases such as cancer. The UCSF team's work showed that these small molecules exhibited high potency and selectivity, making them promising candidates for further preclinical and clinical evaluation.

The synthetic versatility of Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- has also been leveraged in the development of prodrugs. Prodrugs are biologically inactive compounds that are converted into their active forms through metabolic processes within the body. A study published in Organic & Biomolecular Chemistry in 2022 reported the use of this compound to design prodrugs with improved pharmacokinetic properties and reduced toxicity compared to their parent drugs. This approach has significant implications for enhancing the therapeutic index and patient compliance in drug therapy.

Furthermore, Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- has been explored for its potential applications in materials science. Researchers at MIT have investigated its use as a building block for self-assembling supramolecular structures with tunable properties. These structures have shown promise in areas such as drug delivery systems and nanotechnology, where precise control over molecular organization is essential.

The safety profile of Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- has been extensively studied to ensure its suitability for various applications. Toxicological assessments have indicated that this compound exhibits low toxicity when handled under appropriate laboratory conditions. However, it is important to follow standard safety protocols and guidelines to minimize any potential risks associated with its use.

In conclusion, Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- (CAS No. 282525-07-9) is a highly valuable compound with diverse applications in medicinal chemistry, pharmaceutical research, and materials science. Its unique structural features and functional groups make it an indispensable intermediate in the synthesis of bioactive molecules and therapeutic agents. Ongoing research continues to uncover new possibilities for its use in developing innovative solutions to pressing medical challenges.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)